PTPRC and neoplasm: These higher CD45+ immune infiltrates induced by the MuSyC-dose treatment led to an enhanced percentage of CD8+ T cells, CD4+ T cells, NK cells, and CD68+ MACs in the tumor compared to the other groups (Figure 4E).